32 0.18-0.56 6.41 E-05 58 1.21 0.53 2.74 Time from end of initial CT to HDC     NA   60 0.97 0.86-1.09 0.59 Treatment (CCA vs HDC)     NA       NA   PFS, progression-free survival; N, number of cases with data available; 95CI, 95% confidence interval; HR, hazard ratio; OMS, performance status; HDC, Galunisertib datasheet high-dose chemotherapy; CCA, conventional chemotherapy alone. Figure 2 Progression-Free Survival (A) and Overall Survival (B) KU55933 according to chemotherapy regimen in the whole population. Conventional chemotherapy alone (CCA) alone in black, n=103; conventional chemotherapy plus high-dose chemotherapy in grey, n=60, + censored data. We then explored the

prognostic value of the usual clinicopathological features in each treatment arm. We first examined PFS. In the CCA group, PFS was influenced by debulking surgery results (HR=0.29), clinical response to therapy (HR=0.32), and CA125 normalization (HR=0.32). In the HDC arm, age (HR=2.07 if older than 50 years) FIGO stage (HR=0.41 for stage IIIc) and clinical response to initial treatment (HR=0.46) had a prognostic value (Table 3B). When focusing only in the pre-treatment clinicopathological features, only age and FIGO stage had a prognostic value in the HDC group. Impact of HDC on PFS according to these last two features was analyzed. HDC significantly improved PFS in young patients (p=0.02, log-rank test), but had no prognostic GSK461364 value in women older than 50 years (p=0.81, log-rank test), (Figure 3). In the same way,

HDC increased PFS in stage IIIc patients (p=0.03, log-rank test), but not in stage IV cases (p=0.94, log-rank test). Figure 3 Progression-Free Survival according to chemotherapy regimen. Conventional chemotherapy alone (CCA) in black or plus high-dose chemotherapy (HDC) in grey.

(A) In patients under 50 years of age (n=52), median PFS was 11 months in the CCA subset versus 81.7 months in the HDC subset. (B) In patients older than 50 years old (n=111), median PFS was 18.3 months in the CCA subset versus 17.9 months in the HDC subset. + censored data. Cox regression analyses performed in both young patients and stage IIIc cases found that PFS was significantly affected by HDC, surgical results, complete Methane monooxygenase remission and Ca125 normalization after conventional treatment. Young patients had a 2.44-fold rate of progression if they did not receive HDC (Table 4); and stage IIIc patients a 1.61-fold rate of progression if they did not receive HDC (Additional file 1: Table S1). By multivariate analyses HDC had an independent prognostic value in young patients (Table 4), but not in stage IIIc cases (Additional file 1: Table S1). Table 4 Prognostic features (PFS) in young patients (≤50 years), Cox regression analyses   Univariate analysis Multivariate analysis   N HR 95CI p-value N HR 95CI p-value OMS (0-1 vs 2-3) 36 1.76 0.71-4.38 0.22         FIGO (IIIc vs IV) 52 0.57 0.25-1.33 0.19         Histology (serous vs others) 52 0.81 0.51-1.56 0.52         Grade (1-2 vs 3) 31 1.31 0.83-2.08 0.